Extracellular Vesicle MicroRNA in Malignant Pleural Effusion.
EV-miRNA
breast cancer
extracellular vesicle microRNA
lung cancer
malignant pleural effusion
Journal
Genes
ISSN: 2073-4425
Titre abrégé: Genes (Basel)
Pays: Switzerland
ID NLM: 101551097
Informations de publication
Date de publication:
19 11 2022
19 11 2022
Historique:
received:
13
10
2022
revised:
12
11
2022
accepted:
16
11
2022
entrez:
24
11
2022
pubmed:
25
11
2022
medline:
29
11
2022
Statut:
epublish
Résumé
Lung and breast cancer are the two most common causes of malignant pleural effusion (MPE). MPE diagnosis plays a crucial role in determining staging and therapeutic interventions in these cancers. However, our understanding of the pathogenesis and progression of MPE at the molecular level is limited. Extracellular Vesicles (EVs) and their contents, including microRNAs (miRNAs), can be isolated from all bodily fluids, including pleural fluid. This study aims to compare EV-miRNA patterns of expression in MPE caused by breast (BA-MPE) and lung (LA-MPE) adenocarcinomas compared to the control group of heart-failure-induced effusions (HF-PE). We conducted an analysis of 24 pleural fluid samples (8 LA-MPE, 8 BA-MPE, and 8 HF-PE). Using NanoString technology, we profiled miRNAs within EVs isolated from 12 cases. Bioinformatic analysis demonstrated differential expression of miR-1246 in the MPE group vs. HF-PE group and miR-150-5p and miR-1246 in the BA-MPE vs. LA-MPE group, respectively. This difference was demonstrated and validated in an independent cohort using real-time PCR (RT-PCR). miRNA-1246 demonstrated 4-fold increased expression (OR: 3.87, 95% CI: 0.43, 35) in the MPE vs. HF-PE group, resulting in an area under the curve of 0.80 (95% CI: 0.60, 0.99). The highest accuracy for differentiating MPE vs. HF-PE was seen with a combination of miRNAs compared to each miRNA alone. Consistent with prior studies, this study demonstrates dysregulation of specific EV-based miRNAs in breast and lung cancer; pleural fluid provides direct access for the analysis of these EV-miRNAs as biomarkers and potential targets and may provide insight into the underlying pathogenesis of tumor progression. These findings should be explored in large prospective studies.
Identifiants
pubmed: 36421832
pii: genes13112159
doi: 10.3390/genes13112159
pmc: PMC9691121
pii:
doi:
Substances chimiques
MicroRNAs
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NCI NIH HHS
ID : U01 CA213330
Pays : United States
Organisme : NCATS NIH HHS
ID : KL2 TR002648
Pays : United States
Références
Mol Clin Oncol. 2021 Feb;14(2):31
pubmed: 33414912
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
Nat Genet. 2007 Oct;39(10):1278-84
pubmed: 17893677
Cancers (Basel). 2021 Nov 11;13(22):
pubmed: 34830787
PeerJ. 2018 Mar 26;6:e4551
pubmed: 29607263
Nucleic Acids Res. 2012 Dec;40(22):11673-83
pubmed: 23034802
Cell. 2005 Jan 14;120(1):15-20
pubmed: 15652477
Food Chem Toxicol. 2016 Dec;98(Pt A):66-72
pubmed: 27311798
Nucleic Acids Res. 2006 Jul 1;34(Web Server issue):W451-4
pubmed: 16845047
Microsc Res Tech. 2014 Oct;77(10):754-72
pubmed: 25045045
Front Oncol. 2020 Aug 20;10:1454
pubmed: 32974168
Methods Mol Biol. 2019;1970:211-235
pubmed: 30963495
Eur J Cancer. 2014 Mar;50(5):1013-24
pubmed: 24456795
Mol Ther Nucleic Acids. 2019 Jun 7;16:675-685
pubmed: 31121479
Int J Clin Exp Pathol. 2020 Jul 01;13(7):1601-1607
pubmed: 32782678
Lancet. 2002 Jul 27;360(9329):295-305
pubmed: 12147373
PLoS Biol. 2004 Nov;2(11):e363
pubmed: 15502875
Mol Ther Nucleic Acids. 2021 Feb 24;24:542-553
pubmed: 33898106
Cancers (Basel). 2019 Apr 30;11(5):
pubmed: 31052206
Lung Cancer. 2018 Oct;124:45-52
pubmed: 30268479
Hum Mol Genet. 2012 Oct 15;21(R1):R125-34
pubmed: 22872698
J Pers Med. 2020 Oct 11;10(4):
pubmed: 33050659
Sci Rep. 2019 Oct 21;9(1):15057
pubmed: 31636323
J Bronchology Interv Pulmonol. 2021 Oct 1;28(4):310-321
pubmed: 34238837